Related references
Note: Only part of the references are listed.Safety of Very Low Low-Density Lipoprotein Cholesterol Levels With Alirocumab Pooled Data From Randomized Trials
Jennifer G. Robinson et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2017)
Efficacy, safety, Low density lipoprotein cholesterol lowering, and calculated 10year cardiovascular risk reduction of alirocumab and evolocumab in addition to maximal tolerated cholesterol lowering therapy: a post-commercialization study
Parth Shah et al.
LIPIDS IN HEALTH AND DISEASE (2017)
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Marc S. Sabatine et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Long-term Safety and Efficacy of Achieving Very Low Levels of Low-Density Lipoprotein Cholesterol A Prespecified Analysis of the IMPROVE-IT Trial
Robert P. Giugliano et al.
JAMA CARDIOLOGY (2017)
Long-term Low-Density Lipoprotein Cholesterol-Lowering Efficacy, Persistence, and Safety of Evolocumab in Treatment of Hypercholesterolemia Results Up to 4 Years From the Open-Label OSLER-1 Extension Study
Michael J. Koren et al.
JAMA CARDIOLOGY (2017)
Prevalence of heterozygous familial hypercholesterolaemia and its impact on long-term prognosis in patients with very early ST-segment elevation myocardial infarction in the era of statins
Loukianos S. Rallidis et al.
ATHEROSCLEROSIS (2016)
No effect of PCSK9 inhibitor alirocumab on the incidence of diabetes in a pooled analysis from 10 ODYSSEY Phase 3 studies
Helen M. Colhoun et al.
EUROPEAN HEART JOURNAL (2016)
Efficacy of alirocumab in high cardiovascular risk populations with or without heterozygous familial hypercholesterolemia: Pooled analysis of eight ODYSSEY Phase 3 clinical program trials
Michel Farnier et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2016)
Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients The GLAGOV Randomized Clinical Trial
Stephen J. Nicholls et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance The GAUSS-3 Randomized Clinical Trial
Steven E. Nissen et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
Statin intolerance in a referral lipid clinic
Wanda C. Lakey et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2016)
Familial hypercholesterolemia in a large ambulatory population: Statin use, optimal treatment, and identification for advanced medical therapies
Thomas Knickelbine et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2016)
Interpretation of the evidence for the efficacy and safety of statin therapy
Rory Collins et al.
LANCET (2016)
Eligibility for PCSK9 treatment in 734 Hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ≥70 mg/dl despite maximal tolerated cholesterol lowering therapy
Charles J. Glueck et al.
LIPIDS IN HEALTH AND DISEASE (2016)
Pharmacoeconomics of PCSK9 inhibitors in 103 hypercholesterolemic patients referred for diagnosis and treatment to a cholesterol treatment center
Parth Shah et al.
LIPIDS IN HEALTH AND DISEASE (2016)
Focus on PCSK9 Inhibitors: From Genetics to Clinical Practice: Highlights from a CME symposium held at the Cardiometabolic Health Congress (CMHC) Sheraton Boston Hotel, Boston, MA, USA, 23 October 2015
Marc S. Sabatine et al.
POSTGRADUATE MEDICINE (2016)
Efficacy and Safety of Alirocumab 150 mg Every 4 Weeks in Patients With Hypercholesterolemia Not on Statin Therapy: The ODYSSEY CHOICE II Study
Erik Stroes et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2016)
Alirocumab for hyperlipidemia: ODYSSEY Phase III clinical trial results and US FDA approval indications
Eli M. Roth
FUTURE CARDIOLOGY (2016)
Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: The ODYSSEY COMBO I study
Dean J. Kereiakes et al.
AMERICAN HEART JOURNAL (2015)
Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trials
Xin-Lin Zhang et al.
BMC MEDICINE (2015)
Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial
Christopher P. Cannon et al.
EUROPEAN HEART JOURNAL (2015)
Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management
Erik S. Stroes et al.
EUROPEAN HEART JOURNAL (2015)
Statin intolerance - an attempt at a unified definition. Position paper from an International Lipid Expert Panel
Maciej Banach et al.
EXPERT OPINION ON DRUG SAFETY (2015)
New Therapies in the Treatment of High Cholesterol An Argument to Return to Goal-Based Lipid Guidelines
William H. Shrank et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2015)
Reducing LDL with PCSK9 Inhibitors - The Clinical Benefit of Lipid Drugs
Brendan M. Everett et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
Jennifer G. Robinson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events
Marc S. Sabatine et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Lipid-Lowering Drug Therapy for CVD Prevention: Looking into the Future
Evan A. Stein et al.
CURRENT CARDIOLOGY REPORTS (2015)
Statin Intolerance Because of Myalgia, Myositis, Myopathy, or Myonecrosis Can in Most Cases be Safely Resolved by Vitamin D Supplementation
Maksim Khayznikov et al.
NORTH AMERICAN JOURNAL OF MEDICAL SCIENCES (2015)
2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines
David C. Goff et al.
CIRCULATION (2014)
Effect of Evolocumab or Ezetimibe Added to Moderate- or High-Intensity Statin Therapy on LDL-C Lowering in Patients With Hypercholesterolemia The LAPLACE-2 Randomized Clinical Trial
Jennifer G. Robinson et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2014)
2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines
Neil J. Stone et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2014)
Effect of Statins on Skeletal Muscle Function
Beth A. Parker et al.
CIRCULATION (2013)
Differences in cholesterol management among states in relation to health insurance and race/ethnicity across the United States
Stanley H. Hsia et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2013)
Predictors of statin adherence, switching, and discontinuation in the USAGE survey: Understanding the use of statins in America and gaps in patient education
Melissa Y. Wei et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2013)
Effect of Long-Term Exposure to Lower Low-Density Lipoprotein Cholesterol Beginning Early in Life on the Risk of Coronary Heart Disease A Mendelian Randomization Analysis
Brian A. Ference et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2012)
Safety and Efficacy of a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease, SAR236553/REGN727, in Patients With Primary Hypercholesterolemia Receiving Ongoing Stable Atorvastatin Therapy
James M. McKenney et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2012)
Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study
Michael J. Koren et al.
LANCET (2012)
Prevalence of Dyslipidemia and Lipid Goal Attainment in Statin-Treated Subjects From 3 Data Sources: A Retrospective Analysis
Peter H. Jones et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2012)
Vitamin D deficiency, myositis-myalgia, and reversible statin intolerance
Charles J. Glueck et al.
CURRENT MEDICAL RESEARCH AND OPINION (2011)
Lipid Treatment Assessment Project 2 A Multinational Survey to Evaluate the Proportion of Patients Achieving Low-Density Lipoprotein Cholesterol Goals
David D. Waters et al.
CIRCULATION (2009)
Trends in statin use and low-density lipoprotein cholesterol levels among US adults: Impact of the 2001 National Cholesterol Education Program guidelines
Devin Mann et al.
ANNALS OF PHARMACOTHERAPY (2008)
Effect of very high-intensity statin therapy on regression of coronary atherosclerosis - The ASTEROID trial
SE Nissen et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
Genetic causes of monogenic heterozygous familial hypercholesterolemia: A HuGE prevalence review
MA Austin et al.
AMERICAN JOURNAL OF EPIDEMIOLOGY (2004)
Marked low-density lipoprotein cholesterol reduction below Current National Cholesterol Education Program targets provides the greatest reduction in carotid atherosclerosis
SM Kent et al.
CLINICAL CARDIOLOGY (2004)
A review on the diagnosis, natural history, and treatment of familial hypercholesterolaemia
D Marks et al.
ATHEROSCLEROSIS (2003)
ARBITER: Arterial biology for the investigation of the treatment effects of reducing cholesterol - A randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness
AJ Taylor et al.
CIRCULATION (2002)
Validation of the Framingham Coronary Heart Disease prediction scores - Results of a multiple ethnic groups investigation
RB D'Agostino et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2001)
Share Paper
